Table 1 Antitumor efficacy of anti-PD-L1, CM-1758 and CM-1758+anti-PD-L1 in comparison with the control group.

From: Modulation of tumor microenvironment by targeting histone acetylation in bladder cancer

Treatment group

Mean % T/C ( ± SD)

p value

vs. Control

vs. Anti-PD-L1

vs. CM-1758

Anti-PD-L1

74 ± 38

0.112

-

-

CM-1758

70 ± 27

0.023

0.822

-

CM-1758+Anti-PD-L1

62 ± 27

0.006

0.463

0.532

  1. Percentage calculated as [T (tumor) / C (control)] x 100 of growth inhibition by anti-PD-L1, CM-1758 or the combination. Values represented as mean ± SD and p-values < 0.05 were considered statistically significant.
Back to article page